In vivo inhibitory effect of suberoylanilide hydroxamic acid combined with sorafenib on human hepatocellular carcinoma cells. Braz. J. Pharm. Sci. [Internet]. 2020 Dec. 9 [cited 2024 May 16];56:e18254. Available from: https://www.revistas.usp.br/bjps/article/view/181441